History of Mylan Technologies Inc.

The 1980s

Mylan Technologies Inc. starts manufacturing transdermal laminates and extruded films under the name of Bertek Inc. Because of the new company’s capabilities to produce precise coatings, Bertek Inc. becomes a valuable coating and converting source for the pharmaceutical and medical industries.

The 1990s

1992: Bertek begins working with Mylan Laboratories Inc. on a number of transdermal drug delivery products.

1993: Mylan Laboratories Inc. acquires Bertek Inc.

1996: The company receives approval from the Food and Drug Administration (FDA) to manufacture and sell a transdermal Nitroglycerin patch. Mylan Technologies Inc. is the first company to receive approval for a generic transdermal drug delivery system.

1999: Bertek Inc. is renamed Mylan Technologies Inc.

The 2000s

2000: The company receives FDA approval to manufacture and sell a generic seven-day Estrogen patch.

2001: The company commercializes a Nitroglycerin patch in Japan through its marketing partner, and receives regulatory approval to market its Nitroglycerin patch in various European countries.

2005: Mylan Technologies becomes the first company to gain FDA approval for a generic Fentanyl transdermal system.

2006: In February, the FDA approved EMSAM® (selegiline transdermal system). EMSAM® is manufactured by Mylan Technologies for Somerset Pharmaceuticals, Inc., a joint venture between Mylan Laboratories Inc. and Watson Pharmaceuticals, Inc. Mylan Technologies has several other branded and generic transdermal products in various stages of development. The focus on the development of transdermal drug delivery systems has yielded advanced patch designs and constructions covered by U.S. and international patents.

To learn more about the history of Mylan Laboratories Inc., view our interactive history guide.

NOTE: You need to have Macromedia Flash Player installed on your computer in order to view the interactive history. To download a free version of Flash Player, click here